"Another important caveat to our findings is that the threshold for defining cardiotoxicity was set at >30% demonstrating loss of myocardial viability, which limits the definitive interpretation of the results for those drugs with detected viability close to that threshold."
Taxane - Docetaxel - 71.3 ± 6.8%
Topoisomerase inhibitor - Topotecan - 72.2 ± 6.4%
Where does the statistical significance threshold come from? And given these two drugs are close to the threshold, can they also be considered additional potential CPACS opportunities even though HCM viability remained slightly higher than the threshold?
- Forums
- ASX - By Stock
- RAC
- Cardioprotection thread
Cardioprotection thread, page-222
-
-
- There are more pages in this discussion • 684 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.57 |
Change
0.010(0.64%) |
Mkt cap ! $267.5M |
Open | High | Low | Value | Volume |
$1.58 | $1.64 | $1.55 | $134.0K | 84.34K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6283 | $1.57 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.60 | 6559 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6283 | 1.570 |
1 | 3664 | 1.550 |
1 | 1992 | 1.530 |
3 | 32500 | 1.500 |
2 | 3444 | 1.440 |
Price($) | Vol. | No. |
---|---|---|
1.600 | 6559 | 2 |
1.635 | 1270 | 1 |
1.640 | 3000 | 1 |
1.645 | 10000 | 1 |
1.650 | 9735 | 2 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online